Tanabe Pharma said on December 12 that Tanabe Pharma Korea, its consolidated subsidiary, has obtained approval in South Korea for Radicut Suspension (edaravone) to treat amyotrophic lateral sclerosis (ALS). The approval was granted on December 10.Radicut previously received approval in…
To read the full story
Related Article
- Mitsubishi Tanabe’s Oral Edaravone Filed in South Korea
March 14, 2025
BUSINESS
- Chugai to Launch 3 Global PIIIs of Bispecific Antibody NXT007 in 2026
April 27, 2026
- Astellas Bags US$75 Million from MSN after Myrbetriq Patent Settlement
April 27, 2026
- Kura, Kyowa Kirin Start Japan PII Trial of Ziftomenib for AML Filing
April 27, 2026
- Pharma Earnings Season Kicks Off; Off-Year Impact, Overseas Trends in Focus
April 24, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





